BAXTER INTL INC's ticker is BAX and the CUSIP is 071813109. A total of 865 filers reported holding BAXTER INTL INC in Q3 2016. The put-call ratio across all filers is 0.50 and the average weighting 0.3%.
About BAXTER INTL INC
Baxter International Inc. is a global healthcare company that specializes in developing and manufacturing medical products and therapies. The company has a long history of innovation and has been at the forefront of developing life-saving treatments for patients around the world.
Baxter's product portfolio includes a wide range of medical devices, pharmaceuticals, and biotechnology products. The company's products are used in hospitals, clinics, and other healthcare settings to treat a variety of conditions, including hemophilia, immune disorders, kidney disease, and other chronic and acute medical conditions.
Baxter's commitment to innovation has helped the company maintain a strong position in the healthcare industry. The company invests heavily in research and development, and has a strong pipeline of new products in development.
Baxter's leadership team is also a key strength of the company. The CEO, José Almeida, has a strong track record of success in the healthcare industry, and has been instrumental in driving the company's growth and success.
Overall, Baxter International Inc. is a strong and innovative company that is well-positioned to continue delivering value to patients, healthcare providers, and investors alike. With a strong product portfolio, a commitment to innovation, and a talented leadership team, Baxter is a company that investors should keep an eye on in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2018 | $19,068,000 | -16.4% | 293,177 | -16.9% | 2.94% | +4.0% |
Q4 2017 | $22,799,000 | -77.6% | 352,708 | -78.3% | 2.82% | -77.8% |
Q3 2017 | $102,000,000 | -1.6% | 1,625,499 | -5.0% | 12.73% | +4.6% |
Q2 2017 | $103,623,000 | -12.1% | 1,711,643 | -24.7% | 12.17% | -7.6% |
Q1 2017 | $117,927,000 | +7.1% | 2,273,945 | -8.5% | 13.17% | +9.3% |
Q4 2016 | $110,136,000 | -20.7% | 2,483,890 | -14.9% | 12.05% | -23.9% |
Q3 2016 | $138,889,000 | +5.3% | 2,917,846 | +0.0% | 15.82% | -8.9% |
Q2 2016 | $131,910,000 | +24.6% | 2,917,065 | +13.2% | 17.36% | +28.8% |
Q1 2016 | $105,831,000 | – | 2,576,206 | – | 13.47% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
JONES ROAD CAPITAL MANAGEMENT, L.P. | 200,000 | $7,548,000 | 6.60% |
BOONE CAPITAL MANAGEMENT LLC | 469,405 | $17,715,345 | 5.59% |
Soditic Asset Management LLP | 186,920 | $7,054,361 | 5.43% |
JONES ROAD CAPITAL MANAGEMENT, L.P. | 131,000 | $4,943,940 | 4.32% |
Camber Capital Management LP | 3,000,000 | $113,220 | 3.73% |
Carmignac Gestion | 4,848,773 | $182,991,718 | 3.36% |
SHAPIRO CAPITAL MANAGEMENT LLC | 3,028,799 | $114,306,874 | 3.33% |
Hillman Capital Management, Inc. | 219,248 | $8,274,420 | 3.19% |
Cincinnati Specialty Underwriters Insurance CO | 201,500 | $7,604,610 | 2.90% |
Callodine Capital Management, LP | 265,000 | $10,001,100 | 2.79% |